Chromocell Therapeutics Profit Margin

Chromocell Therapeutics posts a profit margin of -1.86% as of March 2026. That is below the sector sector average of 19.69%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

For its sector stocks, a profit margin near 19.69% is typical. Chromocell Therapeutics's -1.86% is lower that level. That is roughly 1045.8% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Chromocell Therapeutics's profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is -1.86% as of March 2026; use YoY and peer views to separate noise from signal.

Context for CHRO's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 19.69%), and (3) consistency with growth and profitability. This page covers the first two; Chromocell Therapeutics's other metric pages and overview cover the third.